This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, K.
Right arrow Articles by Chiocca, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, K.
Right arrow Articles by Chiocca, E. A.

 Previous Article  |  Next Article 

Journal of Virology, May 2000, p. 4765-4775, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant

Keiro Ikeda,1 Hiroaki Wakimoto,1 Tomotsugu Ichikawa,1 Sarah Jhung,2 Fred H. Hochberg,3 David N. Louis,1,2 and E. Antonio Chiocca1,*

Molecular Neuro-Oncology Laboratories, Neurosurgery Service,1 Neurology,3 and Neuropathology,2 Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129

Received 19 August 1999/Accepted 27 January 2000

Intravascular routes of administration can provide a means to target gene- and virus-based therapies to multiple tumor foci located within an organ, such as the brain. However, we demonstrate here that rodent plasma inhibits cell transduction by replication-conditional (oncolytic) herpes simplex viruses (HSV), replication-defective HSV, and adenovirus vectors. In vitro depletion of complement with mild heat treatment or in vivo depletion by treatment of athymic rats with cobra venom factor (CVF) partially reverses this effect. Without CVF, inhibition of cell infection by HSV is observed at plasma dilution as high as 1:32, while plasma from CVF-treated animals displays anti-HSV activity at lower dilutions (1:8). When applied to the therapy of intracerebral brain tumors, in vivo complement depletion facilitates the initial infection (assayed at the 2-day time point) by an intra-arterial replication-conditional HSV of tumor cells, located within three separate and distinct human glioma masses. However, at the 4-day time point, no propagation of HSV from initially infected tumor cells could be observed. Previously, we have shown that the immunosuppressive agent, cyclophosphamide (CPA), facilitates the in vivo propagation of an oncolytic HSV, delivered intravascularly, within infected multiple intracerebral masses, by inhibition of both innate and elicited anti-HSV neutralizing antibody response (K. Ikeda et al., Nat. Med. 5:881-889, 1999). In this study, we thus show that the addition of CPA to the CVF treatment results in a significant increase in viral propagation within infected tumors, measured at the 4-day time period. The concerted action of CVF and CPA significantly increases the life span of athymic rodents harboring three separate and large glioma xenografts after treatment with intravascular, oncolytic HSV. Southern analysis of viral genomes analyzed by PCR reveals the presence of the oncolytic virus in the brains, livers, spleens, kidneys, and intestine of treated animals, although none of these tissues displays evidence of HSV-mediated gene expression. In light of clinical trials of oncolytic HSV for malignant brain tumors, these findings suggest that antitumor efficacy may be limited by the host innate and elicited humoral responses.

* Corresponding author. Mailing address: Molecular Neuro-Oncology Laboratories, Massachusetts General Hospital-East Bldg., CNY6, 13th St., Charlestown, MA 02129. Phone: (617) 726-4684. Fax: (617) 726-5079. E-mail: Chiocca{at}helix.mgh.harvard.edu.

Journal of Virology, May 2000, p. 4765-4775, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kottke, T., Thompson, J., Diaz, R. M., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K., Vile, R. G. (2009). Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. Clin. Cancer Res. 15: 561-569 [Abstract] [Full Text]  
  • King, G. D., Muhammad, A.K.M. G., Curtin, J. F., Barcia, C., Puntel, M., Liu, C., Honig, S. B., Candolfi, M., Mondkar, S., Lowenstein, P. R., Castro, M. G. (2008). Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol Duke 10: 19-31 [Abstract] [Full Text]  
  • Qiao, J., Wang, H., Kottke, T., White, C., Twigger, K., Diaz, R. M., Thompson, J., Selby, P., de Bono, J., Melcher, A., Pandha, H., Coffey, M., Vile, R., Harrington, K. (2008). Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. Clin. Cancer Res. 14: 259-269 [Abstract] [Full Text]  
  • Rhim, J. H., Tosato, G. (2007). Targeting the Tumor Vasculature to Improve the Efficacy of Oncolytic Virus Therapy. JNCI J Natl Cancer Inst 99: 1739-1741 [Full Text]  
  • Fulci, G., Dmitrieva, N., Gianni, D., Fontana, E. J., Pan, X., Lu, Y., Kaufman, C. S., Kaur, B., Lawler, S. E., Lee, R. J., Marsh, C. B., Brat, D. J., van Rooijen, N., Rachamimov, A. S., Hochberg, F. H., Weissleder, R., Martuza, R. L., Chiocca, E. A. (2007). Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses. Cancer Res. 67: 9398-9406 [Abstract] [Full Text]  
  • Li, H., Zeng, Z., Fu, X., Zhang, X. (2007). Coadministration of a Herpes Simplex Virus-2 Based Oncolytic Virus and Cyclophosphamide Produces a Synergistic Antitumor Effect and Enhances Tumor-Specific Immune Responses. Cancer Res. 67: 7850-7855 [Abstract] [Full Text]  
  • Lun, X., Senger, D. L., Alain, T., Oprea, A., Parato, K., Stojdl, D., Lichty, B., Power, A., Johnston, R. N., Hamilton, M., Parney, I., Bell, J. C., Forsyth, P. A. (2006). Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas.. JNCI J Natl Cancer Inst 98: 1546-1557 [Abstract] [Full Text]  
  • Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., Chiocca, E. A. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA 103: 12873-12878 [Abstract] [Full Text]  
  • Kambara, H., Saeki, Y., Chiocca, E. A. (2005). Cyclophosphamide Allows for In vivo Dose Reduction of a Potent Oncolytic Virus. Cancer Res. 65: 11255-11258 [Abstract] [Full Text]  
  • Tyminski, E., LeRoy, S., Terada, K., Finkelstein, D. M., Hyatt, J. L., Danks, M. K., Potter, P. M., Saeki, Y., Chiocca, E. A. (2005). Brain Tumor Oncolysis with Replication-Conditional Herpes Simplex Virus Type 1 Expressing the Prodrug-Activating Genes, CYP2B1 and Secreted Human Intestinal Carboxylesterase, in Combination with Cyclophosphamide and Irinotecan. Cancer Res. 65: 6850-6857 [Abstract] [Full Text]  
  • Shillitoe, E. J., Pellenz, C. (2005). Factors That Limit the Effectiveness of Herpes Simplex Virus Type 1 for Treatment of Oral Cancer in Mice. Clin. Cancer Res. 11: 3109-3116 [Abstract] [Full Text]  
  • Chiocca, E. A. (2005). Oncolytic Viral Therapeutics Based on Herpes Simplex Virus Type I. aacredbook 2005: 139-140 [Full Text]  
  • Huemer, H. P., Wechselberger, C., Bennett, A. M., Falke, D., Harrington, L. (2003). Cloning and expression of the complement receptor glycoprotein C from Herpesvirus simiae (herpes B virus): protection from complement-mediated cell lysis. J. Gen. Virol. 84: 1091-1100 [Abstract] [Full Text]  
  • Brockman, M. A., Knipe, D. M. (2002). Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity. J. Virol. 76: 3678-3687 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»